Introduction
============

Antihypertensive treatment is recommended for secondary prevention in ischemic stroke patients with or without a documented history of hypertension by current American Heart Association/American Stroke Association guidelines.[@b1-ppa-6-911] However, in normal clinical practice, the mechanisms of ischemic stroke may have influenced doctors' decisions to initiate antihypertensive therapies, particularly in patients with severe stenosis or occlusion in intracranial or extracranial arteries, or with nonatherosclerotic mechanisms such as hypercoagulable states, vasculitis, and so on. In this study, we investigated the influence of Trial of Org 10172 in Acute Stroke Treatment (TOAST) subtype on doctors' decisions to use antihypertensive prescriptions at discharge for ischemic stroke patients in a real-world setting.

Methods
=======

Patient data were obtained from the China National Stroke Registry (CNSR), a nationwide, prospective cohort study aimed at identifying vascular risk factors, and documenting the clinical characteristics, diagnosis, and treatments for patients with acute stroke. The detailed protocol of the CNSR has been published elsewhere.[@b2-ppa-6-911] Between September 2007 and August 2008, all consecutive stroke patients aged 18 years or older who were admitted to 132 hospitals within 14 days after the onset of symptoms were recruited. The collection of data for the CNSR was approved by ethics committees at the participating hospitals. Written informed consent was obtained from the patient or his/her legally authorized representative.

The cause of ischemic stroke was classified according to the TOAST criteria,[@b3-ppa-6-911] including large artery atherosclerosis (LAA); small artery occlusion (SAO); cardioembolism (CE); stroke of other determined etiology (SOE); and stroke of undetermined etiology (SUE). In this study, LAA patients were further divided into two groups: moderate stenosis (\<70% stenosis in intracranial or extracranial arteries) and severe stenosis (≥70%). The information about the prescription of antihypertensive medication at discharge was extracted from medical records. Classes of antihypertensive medication included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, beta-blockers, and other antihypertensives including centrally acting adrenergics, peripherally acting antiadrenergics, and vasodilators.

Statistical analysis
--------------------

Univariate and multivariate logistic regression analyses were used to calculate the crude and adjusted odds ratios (ORs), respectively, for the association between TOAST subtypes and the prescription of antihypertensive medication at discharge. The multivariate models were created using variables associated with antihypertensive medication prescription (gender, age, monthly household income, types of health insurance, hypertension, diabetes mellitus, dyslipidemia, coronary heart disease, atrial fibrillation, history of stroke, previous antihypertensive medication use, and systolic blood pressure at discharge). Effect sizes were expressed as ORs and 95% confidence intervals (CIs). Two-tailed statistical significance was defined as *P* \< 0.05. All statistical analyses were performed using SAS 9.1.3 (SAS Institute Inc, Cary, NC, USA).

Results
=======

Patients' characteristics
-------------------------

A total of 12,063 ischemic stroke patients were analyzed in this study, with a mean age at entry of 65.4 ± 11.6 years; 38.0% of the patients were women, 33.8% had a history of stroke, 70.8% had hypertension, 28.0% had diabetes, and 55.0% had dyslipidemia ([Table 1](#t1-ppa-6-911){ref-type="table"}). Among all ischemic stroke subjects with or without hypertension, 4742 patients (39.3%) received a prescription at discharge for any antihypertensive, among whom 14 (0.3%) were discharged on four or more antihypertensive agents, 266 (5.6%) were discharged on three, 949 (20.0%) on two, and 3513 (74.1%) on one.

Influence of TOAST subtype upon antihypertensive prescription at discharge
--------------------------------------------------------------------------

The multivariate analysis showed that when compared with LAA patients with moderate (\<70%) stenosis, the adjusted ORs with 95% CIs were 0.72 (0.59--0.88), 1.50 (1.33--1.69), 0.91 (0.72--1.15), 1.49 (0.95--2.32), and 0.71 (0.64--0.79) in LAA patients with severe (≥70%) stenosis, SAO, CE, SOE, and SUE patients, respectively ([Table 1](#t1-ppa-6-911){ref-type="table"}).

Other predictors of antihypertensive prescription at discharge
--------------------------------------------------------------

Multivariate analysis showed that patients with hypertension, diabetes, dyslipidemia, high income, urban employee health insurance, and high systolic blood pressure at discharge were more likely to be prescribed with antihypertensive medication at discharge; however, the elderly were less likely to be prescribed ([Table 1](#t1-ppa-6-911){ref-type="table"}).

Subgroup analyses
-----------------

We also investigated the influence of the TOAST subtype on antihypertensive prescription at discharge in patients with hypertension. The multivariate analysis showed that when compared with LAA patients with moderate (\<70%) stenosis, the adjusted ORs with 95% CI were 0.70 (0.57--0.86), 1.57 (1.38--1.78), 0.89 (0.69--1.14), 1.47 (0.90--2.41), and 0.71 (0.64--0.79) in LAA patients with severe (≥70%) stenosis, SAO, CE, SOE, and SUE patients, respectively. This was similar to the group at large.

Discussion
==========

In normal clinical practice, given the level of concern over stroke recurrence from hypoperfusion, most neurologists tend to hold conservative attitudes toward active antihypertensive treatments for ischemic stroke patients. Our results indicated that the TOAST subtype had an influence on doctors' decisions to use antihypertensive prescriptions at discharge for ischemic stroke patients in real-world settings. Doctors tend to prescribe antihypertensives for SAO patients, but they are very cautious in prescribing them for LAA patients with severe stenosis. Unfortunately, to date there are no guidelines that have given definite recommendations as to how to choose the appropriate antihypertensive treatment for patients with different TOAST subtypes. The doctors' decisions are only based on personal experience in clinical practice. Therefore, more evidence from clinical trials and recommendations from guidelines are needed for this decision.

Although current American Heart Association/American Stroke Association guidelines advocate that blood reduction is also reasonable for ischemic stroke patients without hypertension,[@b1-ppa-6-911] our study showed that only 5.5% of nonhypertensive ischemic stroke patients were prescribed antihypertensive medications. This finding may reflect the influence of clinical trial results that suggest that nonhypertensive stroke patients may reap benefits from antihypertensive treatments.[@b4-ppa-6-911] However, these agents may have been prescribed for other therapeutic reasons, such as using beta-blockers for heart rate control, or angiotensin-converting enzyme inhibitors for heart failure.[@b5-ppa-6-911]
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Prescription of AH medication at discharge for ischemic stroke patients

  Variables                                                    Prescription of AHs at discharge   Crude OR       Adjusted OR            
  ------------------------------------------------------------ ---------------------------------- -------------- ---------------------- ----------------------
  Total                                                        12,063                             4742 (39.3)                           
  TOAST subtype                                                                                                                         
   LAA (stenosis \< 70%)                                       4885                               2098 (43.0)    Reference              Reference
   LAA (stenosis ≥ 70%)                                        583                                220 (37.7)     0.81 (0.68--0.96)      0.72 (0.59--0.88)
   SAO                                                         2076                               1050 (50.6)    1.36 (1.23--1.51)      1.50 (1.33--1.69)
   CE                                                          690                                226 (32.8)     0.65 (0.55--0.77)      0.91 (0.72--1.15)
   SOE                                                         134                                55 (41.0)      0.93 (0.65--1.31)      1.49 (0.95--2.32)
   SUE                                                         3695                               1093 (29.6)    0.56 (0.51--0.61)      0.71 (0.64--0.79)
  Sex                                                                                                                                   
   Male                                                        7474                               2895 (38.7)    Reference              Reference
   Female                                                      4589                               1847 (40.3)    1.07 (0.99--1.15)      1.00 (0.91--1.09)
  Age                                                                                                                                   
   18--45                                                      773                                269 (34.8)     Reference              Reference
   46--65                                                      4940                               1942 (39.3)    1.21 (1.04--1.42)      0.79 (0.68--1.02)
   66--75                                                      3716                               1550 (41.7)    1.34 (1.14--1.58)      0.78 (0.70--1.06)
   ≥76                                                         2634                               981 (37.2)     1.11 (0.94--1.32)      0.70 (0.56--0.86)
  Monthly household income, yuan                                                                                                        
    ≤500                                                       1384                               503 (36.3)     Reference              Reference
   500--1000                                                   2793                               1161 (41.6)    1.25 (1.09--1.42)      1.05 (0.90--1.23)
   1001--3000                                                  4033                               1768 (43.8)    1.37 (1.21--1.55)      1.04 (0.89--1.22)
    ≥3000                                                      815                                402 (49.3)     1.71 (1.43--2.03)      1.27 (1.03--1.57)
   Unknown                                                     3038                               908 (29.9)     0.75 (0.65--0.85)      0.62 (0.53--0.72)
  Types of health insurance                                                                                                             
   Own expense                                                 2305                               799 (34.7)     Reference              Reference
   Urban employee                                              7293                               3077 (42.2)    1.38 (1.24--1.52)      1.21 (1.07--1.36)
   Rural cooperative                                           2075                               705 (40.0)     0.97 (0.86--1.10)      1.10 (0.95--1.27)
   Commercial and other                                        390                                161 (41.3)     1.36 (1.06--1.65)      1.12 (0.96--1.26)
  Hypertension                                                                                                                          
   No                                                          3520                               192 (5.5)      Reference              Reference
   Yes                                                         8543                               4550 (53.26)   19.75 (16.97--22.98)   16.54 (13.99--19.55)
  Diabetes                                                                                                                              
   No                                                          8682                               3211 (37.0)    Reference              Reference
   Yes                                                         3381                               1531 (45.3)    1.41 (1.30--1.53)      1.10 (1.01--1.20)
  Dyslipidemia                                                                                                                          
   No                                                          5424                               1678 (30.9)    Reference              Reference
   Yes                                                         6639                               3064 (46.2)    1.91 (1.78--2.06)      1.61 (1.48--1.76)
  Coronary artery disease                                                                                                               
   No                                                          10,357                             4015 (38.8)    Reference              Reference
   Yes                                                         1706                               727 (42.6)     1.17 (1.06--1.30)      0.89 (0.79--1.01)
  Atrial fibrillation                                                                                                                   
   No                                                          10,875                             4333 (39.8)    Reference              Reference
   Yes                                                         1188                               409 (34.4)     0.79 (0.70--0.90)      1.00 (0.83--1.20)
  History of stroke                                                                                                                     
   No                                                          7982                               3036 (38.0)    Reference              Reference
   Yes                                                         4081                               1706 (41.8)    1.17 (1.08--1.26)      0.94 (0.86--1.03)
  History of AH medication                                                                                                              
   No                                                          6430                               1692 (26.3)    Reference              Reference
   Yes                                                         5633                               3050 (54.2)    3.31 (3.06--3.57)      1.08 (0.98--1.19)
  SBP at discharge[\*](#tfn2-ppa-6-911){ref-type="table-fn"}                                                                            
   \<120 mmHg                                                  649                                99 (2.1)       Reference              Reference
   120--139 mmHg                                               2558                               711 (15.1)     2.14 (1.70--2.69)      1.58 (1.21--2.05)
   140--159 mmHg                                               4538                               1727 (36.6)    3.41 (2.73--4.26)      1.87 (1.45--2.41)
   ≥160 mmHg                                                   4265                               2176 (46.2)    5.79 (4.63--7.23)      2.65 (2.06--3.42)

**Note:**

SBP at discharge data was missing for a total of 53 patients.

**Abbreviations:** AH, antihypertensive; n, number; OR, odds ratio; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SAO, small artery occlusion; CE, cardioembolism; SOE, stroke of other determined etiology; SUE, stroke of undetermined etiology; SBP, systolic blood pressure.
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